39.00
-2.74%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About HeXun Biosciences Co
Its shares trade on Taipei Exchange under the ticker 6986.TWO. It has been listed since 7 September 2023. In the fiscal year to 31 December 2025, it reported revenue of TWD 293.2m and net income of TWD 111.9m. At that date it held total assets of TWD 837.1m and shareholders' equity of TWD 741.6m.
HeXun Biosciences Co Ltd is a TW-based company operating in Life Sciences Tools & Services industry. The company is headquartered in Taoyuan, Taoyuan. The company went IPO on 2023-09-07. HeXun Biosciences Co Ltd is a Taiwan-based company primarily engaged in the drug development business. The firm's products and services are mainly new drug development and sales, contract development and manufacturing services, testing services and other services. The firm's cellular products are categorized into allogeneic mesenchymal stem cell drugs and autologous cell medical technology development cellular products. The firm is also engaged in the provision of aseptic filling services, Good Tissue Practice (GTP) laboratory setup and quality documentation counseling services, and laboratory information management systems. The firm sells its products and services primarily domestically.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Life Sciences Tools & Services
- Listed since
- 7 Sept 2023
- Website
- hexunbio.com ↗
Leadership
Pay as last reported
- Mr. Zhenghan WenChairman of the Board, since 2019TWD 3.2m
- Mr. Yushen LanManager of Finance & Accounting
- Mr. Chi-Hung HuangGeneral Manager, DirectorTWD 3.2m
- Mr. Songyuan ChenDeputy General Manager
- Ms. Wanxin ChenDeputy General Manager-R&D
- Mr. Hong-Wen ChenDirector
- Mr. Ming-Hsien ChenDirector
- Mr. Chien Cheng ChuIndependent DirectorTWD 74,000
- Ms. Tsai Wei TsaiIndependent DirectorTWD 74,000
- Mr. Tzong-Der WayIndependent DirectorTWD 74,000
- Ms. Yubei LiaoHead of Administration DivisionTWD 2.6m
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- HeXun Biosciences operates in Life Sciences Tools & Services industry with a focus on drug development in Taiwan.
- HeXun Biosciences offers allogeneic mesenchymal stem cell drugs and autologous cell medical technology development.
- HeXun Biosciences provides aseptic filling services and GTP laboratory setup in Taoyuan, Taiwan.
Weaknesses
- HeXun Biosciences primarily sells products domestically in Taiwan with limited international market presence.
- HeXun Biosciences has a single headquarters city, Taoyuan, which may limit regional diversification.
- HeXun Biosciences' business is concentrated on drug development without diversification into other sectors.
Opportunities
- HeXun Biosciences can expand into international markets beyond Taiwan for drug development services.
- HeXun Biosciences can leverage its cellular products for global health care applications.
- HeXun Biosciences can grow its contract development and manufacturing services in the Life Sciences Tools & Services industry.
Threats
- HeXun Biosciences faces competition from other Life Sciences Tools & Services companies in Taiwan.
- HeXun Biosciences must comply with strict regulations in the Health Care sector in Taiwan.
- HeXun Biosciences could be affected by economic downturns in the Taiwan market.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.